Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001326732-24-000060
Filing Date
2024-11-06
Accepted
2024-11-06 16:09:09
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q xncr-20240930.htm   iXBRL 10-Q 1275156
2 EX-31.1 xncr-20240930xexx311.htm EX-31.1 10221
3 EX-31.2 xncr-20240930xexx312.htm EX-31.2 10067
4 EX-32.1 xncr-20240930xexx321.htm EX-32.1 6411
  Complete submission text file 0001326732-24-000060.txt   7219917

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xncr-20240930.xsd EX-101.SCH 46286
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xncr-20240930_cal.xml EX-101.CAL 79573
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xncr-20240930_def.xml EX-101.DEF 239704
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xncr-20240930_lab.xml EX-101.LAB 661144
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xncr-20240930_pre.xml EX-101.PRE 468764
72 EXTRACTED XBRL INSTANCE DOCUMENT xncr-20240930_htm.xml XML 1042221
Mailing Address 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107
Business Address 465 N. HALSTEAD ST. SUITE 200 PASADENA CA 91107 626-305-5900
Xencor Inc (Filer) CIK: 0001326732 (see all company filings)

EIN.: 201622502 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36182 | Film No.: 241430977
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)